tetano
Editor, Senior Moderator
ACG Case Rep J
. 2023 Aug 17;10(8):e01114.
doi: 10.14309/crj.0000000000001114. eCollection 2023 Aug. Fulminant Presentation of Budd-Chiari Syndrome Secondary to COVID-19 Infection
Harshavardhan Sanekommu[SUP] 1 [/SUP], Sobaan Taj[SUP] 1 [/SUP], Catherine Kilada[SUP] 2 [/SUP], Jayasree Ravilla[SUP] 3 [/SUP], Claudia Ramirez[SUP] 1 [/SUP], Paula Espinosa Gonzalez[SUP] 1 [/SUP], Steven Imburgio[SUP] 1 [/SUP], Anmol Johal[SUP] 1 [/SUP], Xiu Sun[SUP] 4 [/SUP], Pranav N Shah[SUP] 5 [/SUP], Mohammad Hossain[SUP] 1 [/SUP]
Affiliations
Budd-Chiari syndrome (BCS) is a rare condition characterized by the obstruction of hepatic venous outflow. It is estimated to affect 1 in 100,000 people worldwide. In cases of new BCS, inherited and acquired hypercoagulability states must be evaluated. Coronavirus disease 2019 (COVID-19) can induce a hypercoagulable state because of its extensive inflammatory response, and while it has been reported to cause portal vein thrombosis, it rarely causes BCS. This article presents a case of a 22-year-old man who developed fulminant symptoms and was subsequently diagnosed with BCS and portal vein thrombosis secondary to COVID-19 infection, after ruling out other inherited and acquired causes of BCS. In addition, a literature review is provided to understand the presentation and management of such patients. Although most patients improve with medical management, this article emphasizes the consideration of liver transplant for patients who do not improve.
Keywords: Budd-Chiari Syndrome; COVID 19; anticoagulation; portal vein thrombosis.
. 2023 Aug 17;10(8):e01114.
doi: 10.14309/crj.0000000000001114. eCollection 2023 Aug. Fulminant Presentation of Budd-Chiari Syndrome Secondary to COVID-19 Infection
Harshavardhan Sanekommu[SUP] 1 [/SUP], Sobaan Taj[SUP] 1 [/SUP], Catherine Kilada[SUP] 2 [/SUP], Jayasree Ravilla[SUP] 3 [/SUP], Claudia Ramirez[SUP] 1 [/SUP], Paula Espinosa Gonzalez[SUP] 1 [/SUP], Steven Imburgio[SUP] 1 [/SUP], Anmol Johal[SUP] 1 [/SUP], Xiu Sun[SUP] 4 [/SUP], Pranav N Shah[SUP] 5 [/SUP], Mohammad Hossain[SUP] 1 [/SUP]
Affiliations
- PMID: 37601303
- PMCID: PMC10435036
- DOI: 10.14309/crj.0000000000001114
Budd-Chiari syndrome (BCS) is a rare condition characterized by the obstruction of hepatic venous outflow. It is estimated to affect 1 in 100,000 people worldwide. In cases of new BCS, inherited and acquired hypercoagulability states must be evaluated. Coronavirus disease 2019 (COVID-19) can induce a hypercoagulable state because of its extensive inflammatory response, and while it has been reported to cause portal vein thrombosis, it rarely causes BCS. This article presents a case of a 22-year-old man who developed fulminant symptoms and was subsequently diagnosed with BCS and portal vein thrombosis secondary to COVID-19 infection, after ruling out other inherited and acquired causes of BCS. In addition, a literature review is provided to understand the presentation and management of such patients. Although most patients improve with medical management, this article emphasizes the consideration of liver transplant for patients who do not improve.
Keywords: Budd-Chiari Syndrome; COVID 19; anticoagulation; portal vein thrombosis.